Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Rhea-AI Summary
Graviton BioScience received FDA Investigational New Drug (IND) clearance on August 7, 2026 for a novel capsule formulation of GV101, a selective ROCK2 inhibitor being developed as an oral treatment for Friedreich's ataxia (FA). The clearance allows initiation of a randomized, placebo-controlled, 12-week Phase 2 trial, enrolling up to 48 participants at multiple U.S. and international sites starting in the first quarter of 2027. According to Graviton BioScience, GV101 has shown favorable safety in over 500 clinical participants and has increased frataxin mRNA and protein levels in preclinical and clinical studies, supporting its potential as a disease-modifying therapy targeting the underlying frataxin deficiency in FA.
Positive
- FDA IND clearance for GV101 capsule on August 7, 2026, enabling Phase 2 in FA
- Planned 12-week Phase 2 trial with up to 48 participants, randomized and placebo-controlled
- GV101 clinical exposure in 500+ participants up to 24 weeks, with extensions beyond one year
- Phase 1 data showed improved PK and oral bioavailability for GV101 capsule in healthy volunteers
- GV101 increased frataxin mRNA and protein levels in multiple preclinical and clinical systems
Negative
- None.
News Explained
The planned Phase 2 trial will test the capsule formulation’s dose range, safety, tolerability, and frataxin-level response; participants may continue approved standard-of-care treatment, with enrollment expected in
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Inducement grant | Neutral | +2.2% | Equity awards approved for a new employee under Nasdaq listing rules. |
| Jul 07 | Strategic investment | Positive | +5.5% | Up to $400 million investment supported gene therapy development and commercialization. |
| May 14 | Inducement grant | Neutral | -5.5% | Equity awards approved for the incoming Chief Development Officer. |
| May 14 | Earnings report | Neutral | -0.2% | Quarterly results included pipeline, financing, deal, and regulatory updates. |
| Apr 16 | Public offering | Negative | -15.7% | Underwritten offering priced 11,111,111 ordinary shares for approximately $100 million. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mostly aligned with event direction, with one notable divergence among the five selected events.
Key Terms
investigational new drug regulatory
pharmacokinetic medical
oral bioavailability medical
peripheral blood mononuclear cells medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Graviton received Investigational New Drug (IND) clearance from the
U.S . Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. - FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
- GV101 is a best-in-class selective ROCK2 inhibitor that increases frataxin protein levels, a therapeutic approach with potential disease-modifying effects in Friedreich's ataxia.
"Our preclinical work has suggested that ROCK2 inhibition in cells derived from FA patients increased frataxin significantly. ROCK2 inhibition also increased frataxin in PBMCs in patients receiving GV101 in an obesity study. We believe, therefore, that this induction of frataxin by GV101 may become an orally available disease modifying agent." Rui Wu, Head of Research and Preclinical
Planned Phase 2 Study in Friedreich's Ataxia
GV101 is one of Graviton's proprietary investigational oral ROCK2 inhibitors advancing within the Company's broader development pipeline. The planned Phase 2 study will utilize a novel capsule formulation of GV101 that demonstrated improved pharmacokinetic (PK) properties and oral bioavailability in healthy volunteers in a Phase 1 study. This formulation of GV101 is being developed as a potential treatment for Friedreich's ataxia, a rare genetic disease driven by deficient frataxin production.
Graviton now plans to initiate a 12-week, randomized, placebo-controlled, dose-finding Phase 2 trial enrolling up to 48 participants at multiple sites in
The Phase 2 study will be followed by an open-label extension, offering active drug to all participants who complete the 12-week trial. Participants will be able to continue receiving their existing FDA-approved standard-of-care treatment throughout the study while taking GV101. Enrollment is expected to begin in the first quarter of 2027.
GV101 Development Highlights
GV101 has demonstrated a favorable safety and tolerability profile in preclinical and clinical studies. More than 500 participants have received GV101 in clinical studies for durations of up to 24 weeks, with extension studies exceeding one year. In a Phase 1 multiple ascending dose study in healthy volunteers, GV101 achieved clinically relevant exposure and demonstrated a favorable safety and tolerability profile.
Preclinical and clinical studies have also demonstrated that GV101 increases both frataxin mRNA and protein levels in patient-derived B-lymphocytes and fibroblasts. Consistent with these findings, oral ROCK2 inhibition with GV101 increased frataxin levels in vivo in an obesity study that evaluated patient-derived peripheral blood mononuclear cells (PBMCs).
Collectively, these results provide evidence that ROCK2 inhibition may increase frataxin expression across multiple experimental systems. Increasing frataxin protein levels has the potential to move patients toward levels observed in asymptomatic carriers, supporting GV101's potential as a disease-modifying therapy aimed at addressing the underlying cause of Friedreich's ataxia.
About Friedreich's Ataxia
Friedreich's ataxia (FA) is a rare, inherited, progressive neurodegenerative disease affecting approximately 5,000 people in
About GV101
GV101 is a clinical-stage, best-in-class, selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2). ROCK2 is a key regulator of multiple cellular pathways involved in inflammation, fibrosis, metabolism, and gene expression. Through selective inhibition of ROCK2, GV101 has demonstrated the potential to modulate disease-relevant biological processes, including increasing frataxin production, a key factor in Friedreich's ataxia.
About Graviton BioScience
Graviton BioScience Corporation is a clinical-stage drug discovery and development company dedicated to engineering and developing best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and other disease indications. Graviton has developed a portfolio of selective ROCK2 inhibitors among other safe, innovative, and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. GV101 is in clinical studies, with additional assets advancing through the pipeline. Leading the Company is Dr. Samuel Waksal, the founder and former Chairman and CEO of Kadmon Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).
Forward-Looking Statements
This press release contains forward-looking statements regarding Graviton's development plans, regulatory strategy, and potential future clinical applications for its selective ROCK2 inhibitors. Such statements are subject to risks and uncertainties, including, but not limited to, biological, clinical, regulatory, financial, and operational risks. Actual results may differ materially.
Graviton BioScience Contact
Melanie Glickman
Senior Associate, Operations Strategy
Melanie.Glickman@gravitoncorp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/graviton-bioscience-announces-clearance-of-investigational-new-drug-ind-for-gv101-for-the-treatment-of-friedreichs-ataxia-302848536.html
SOURCE Graviton Bioscience Corporation